News >

Slamon Specifies Next Steps in Ovarian Cancer Treatment

Caroline Seymour
Published: Tuesday, Jul 03, 2018

Dennis J. Slamon, MD, PhDDennis J. Slamon, MD, PhD

Although PARP inhibitors were intended to treat patients who harbor germline BRCA mutations, Dennis J. Slamon, MD, PhD, explained that the future of PARP inhibition is likely to lie in combination and at full dose.

Niraparib (Zejula), for example, has shown efficacy in patients with platinum-resistant/refractory ovarian cancer when in combination with pembrolizumab (Keytruda). Data from the recurrent ovarian cancer cohort of the phase I/II TOPACIO/KEYNOTE-162 trial showed an objective response rate of 25% and disease control rate of 67% in the 60 evaluable patients.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication